FDA warning against high dose antidepressant prescription may be unwarranted, study finds

May 3, 2013

The U.S. Food and Drug Administration's warning that high doses of the antidepressant citalopram can cause potentially serious abnormal heart rhythms might be doing more harm than good.

In 2011, the FDA attached a warning to the drug, also known as Celexa, based on data linking higher doses of the drug to potentially fatal in the of the heart.

The new Ann Arbor VA Healthcare System and University of Michigan study, however, calls into question the FDA's warning after finding no increased risk for or death in patients who took daily doses of more than 40 milligrams before or after the warning took effect.

Since the warning went into effect, physicians have begun to limit citalopram prescriptions, even though higher doses can offer relief to some high-risk depression patients.

The study, which was published online today in the American Journal of Psychiatry, is the largest analysis to date of outcomes related to citalopram use.

"Our findings raise questions about the continued legitimacy of the FDA warning and provide support for the question of whether the warning will do more harm than good," says Kara Zivin, Ph.D., assistant professor of psychiatry at U-M, research investigator at the VA Center for Research (CCMR) and the study's lead author.

Helen Kales, M.D., associate professor of psychiatry, research investigator at CCMR, and the study's senior author added, "For some patients, a dosage higher than 40 milligrams per day can be very beneficial. Unfortunately the FDA's warning may have made attaining such a prescription more difficult."

The researchers analyzed data from more than 600,000 Veterans Health Administration patients who received citalopram prescriptions between 2004 and 2009. The study also examined for more than 300,000 patients who were prescribed a similar antidepressant, sertraline, which does not have an FDA warning.

Results indicated no elevated risks of ventricular arrhythmia or death related to higher dosages of citalopram. In fact, higher dosages were associated with fewer adverse outcomes than lower dosages. Similar findings were observed in the comparison drug , which is prescribed without warning.

Zivin says additional exploration into the possible link between citalopram and cardiac risks will be necessary to provide further guidance to clinicians who are considering the drug for their patients. The new results, which appear to contradict the basis for the FDA's warning, present clinicians with a conundrum.

For example, Zivin notes, physicians may wonder, "Should dosages be modified for those with risk factors for cardiac complications? Should health care providers alter how they prescribe this drug to new patients, or order ECGs for patients at risk before writing a new prescription? Or should patients be switched to other antidepressants with similar profiles, but no warning? These are all things clinicians need to consider."

She adds, "Currently, clinicians whose patients benefit from high dosages of must choose between following the FDA's warning or risking worsening depression if patients receive too low a dosage."

Zivin says she and her research group are exploring options for further studies examining how the warning has influenced patients' use of the drug.

Explore further: FDA warns of heart risks with high doses of Celexa

More information: "Evaluation of the FDA Warning Against Prescribing Citalopram at Doses Exceeding 40 mg" American Journal of Psychiatry (2013)

Related Stories

FDA adds more warnings to antidepressant's label

March 28, 2012

(HealthDay) -- In a follow-up to a warning that high doses of the popular antidepressant Celexa can cause potentially fatal abnormal heart rhythms, the U.S. Food and Drug Administration has issued new dosing and use recommendations.

Recommended for you

Watching eyes prevent littering

December 1, 2015

People are less likely to drop litter if it has printed eyes on it, researchers at Newcastle University, UK, have found. An image of watching eyes reduced the odds of littering by around two thirds.

Anxiety can kill your social status

December 1, 2015

Neuroscientists at EPFL identify a brain region that links anxious temperament to low social status. The researchers were able to tweak social hierarchy in animals by using vitamin B3.

How can I tell if she's lying?

November 27, 2015

Sarcasm, white lies and teasing can be difficult to identify for those with certain disorders – new video inventory developed at McGill may help


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.